Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

Iovance Biotherapeutics (IOVA) was in the spotlight on Friday after the biotech firm reported promising results from a Phase 2 trial of its experimental cell therapy Lifileucel,…

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (stocktwits.com)